INNOVIVA, INC. Revenues
INNOVIVA, INC. (INVA) reported Revenues of $67.09 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-07-26.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2018-07-26
- INNOVIVA, INC. revenues for the quarter ending 2018-06-30 was $67.09M, a 14.56% increase year-over-year.
- INNOVIVA, INC. revenues for the quarter ending 2018-03-31 was $52.38M, a 29.36% increase year-over-year.
- INNOVIVA, INC. revenues for the quarter ending 2017-12-31 was $69.52M, a 59.41% increase year-over-year.
- INNOVIVA, INC. revenues for the quarter ending 2017-09-30 was $48.64M, a 46.04% increase year-over-year.
- INNOVIVA, INC. revenues for fiscal 2017 was $217.22M, a 62.63% increase from fiscal 2016.
- INNOVIVA, INC. revenues for fiscal 2016 was $133.57M, a 147.58% increase from fiscal 2015.
- INNOVIVA, INC. revenues for fiscal 2015 was $53.95M, a 539.74% increase from fiscal 2014.
- INNOVIVA, INC. revenues for fiscal 2014 was $8.43M, a 86.08% increase from fiscal 2013.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 9 month | Revenues 12 month | Revenues 12 month as first filed |
|---|---|---|---|---|---|---|
| 2018-06-30 | $67.09M 10-Q · filed 2018-07-26 | $119.47M 10-Q · filed 2018-07-26 | $188.99M derived: sum of 3 quarters · filed 2018-07-26 | $237.63M derived: sum of 4 quarters · filed 2018-07-26 | ||
| 2018-03-31 | $52.38M 10-Q · filed 2018-05-04 | $121.90M derived: sum of 2 quarters · filed 2018-05-04 | $170.54M derived: sum of 3 quarters · filed 2018-05-04 | $229.10M derived: sum of 4 quarters · filed 2018-07-26 | ||
| 2017-12-31 | $69.52M 10-K · filed 2018-02-23 | $118.16M derived: sum of 2 quarters · filed 2018-02-23 | $176.72M derived: sum of 3 quarters · filed 2018-07-26 | $217.22M 10-K · filed 2018-02-23 | ||
| 2017-09-30 | $48.64M 10-K · filed 2018-02-23 | $107.20M derived: sum of 2 quarters · filed 2018-07-26 | $147.70M 10-Q · filed 2017-11-03 | $191.31M derived: sum of 4 quarters · filed 2018-07-26 | ||
| 2017-06-30 | $58.56M 10-Q · filed 2018-07-26 | $99.05M 10-Q · filed 2018-07-26 | $142.67M derived: sum of 3 quarters · filed 2018-07-26 | $175.97M derived: sum of 4 quarters · filed 2018-07-26 | ||
| 2017-03-31 | $40.49M 10-Q · filed 2018-05-04 | $84.10M derived: sum of 2 quarters · filed 2018-05-04 | $117.41M derived: sum of 3 quarters · filed 2018-05-04 | $149.88M derived: sum of 4 quarters · filed 2018-05-04 | ||
| 2016-12-31 | $43.61M 10-K · filed 2018-02-23 | $76.92M derived: sum of 2 quarters · filed 2018-02-23 | $109.39M derived: sum of 3 quarters · filed 2018-02-23 | $133.57M 10-K · filed 2018-02-23 | ||
| 2016-09-30 | $33.31M 10-K · filed 2018-02-23 | $65.78M derived: sum of 2 quarters · filed 2018-02-23 | $89.96M 10-Q · filed 2017-11-03 | $112.79M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2016-06-30 | $32.47M 10-K · filed 2018-02-23 | $56.65M 10-Q · filed 2017-08-08 | $79.48M derived: sum of 3 quarters · filed 2018-02-23 | $93.05M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2016-03-31 | $24.18M 10-K · filed 2018-02-23 | $47.01M derived: sum of 2 quarters · filed 2018-02-23 | $60.57M derived: sum of 3 quarters · filed 2018-02-23 | $71.23M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2015-12-31 | $22.84M 10-K · filed 2017-02-28 | $36.40M derived: sum of 2 quarters · filed 2017-02-28 | $47.05M derived: sum of 3 quarters · filed 2017-02-28 | $53.95M 10-K · filed 2018-02-23 | ||
| 2015-09-30 | $13.56M 10-K · filed 2017-02-28 | $24.22M derived: sum of 2 quarters · filed 2017-02-28 | $31.11M 10-Q · filed 2016-11-03 | $38.39M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-06-30 | $10.65M 10-K · filed 2017-02-28 | $17.55M 10-Q · filed 2016-08-04 | $24.83M derived: sum of 3 quarters · filed 2017-02-28 | $25.83M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-03-31 | $6.90M 10-K · filed 2017-02-28 | $14.18M derived: sum of 2 quarters · filed 2017-02-28 | $15.18M derived: sum of 3 quarters · filed 2017-02-28 | $16.11M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2014-12-31 | $7.28M 10-K · filed 2016-02-24 | $8.28M derived: sum of 2 quarters · filed 2016-02-24 | $9.21M derived: sum of 3 quarters · filed 2016-02-24 | $8.43M 10-K · filed 2017-02-28 | ||
| 2014-09-30 | $999.00K 10-K · filed 2016-02-24 | $1.93M derived: sum of 2 quarters · filed 2016-02-24 | $1.15M 10-Q · filed 2015-11-05 | $2.63M derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2014-06-30 | $934.00K 10-K · filed 2016-02-24 | $154.00K 10-Q · filed 2015-08-06 | $1.63M derived: sum of 3 quarters · filed 2016-02-24 | $2.04M derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2014-03-31 | -$780.00K 10-K · filed 2016-02-24 | $165.00K 10-Q · filed 2014-05-07 | $693.00K derived: sum of 2 quarters · filed 2016-02-24 | $1.11M derived: sum of 3 quarters · filed 2016-02-24 | $2.43M derived: sum of 4 quarters · filed 2016-02-24 | |
| 2013-12-31 | $1.47M 10-K · filed 2015-02-27 | $1.89M derived: sum of 2 quarters · filed 2015-02-27 | $3.21M derived: sum of 3 quarters · filed 2015-02-27 | $4.53M 10-K · filed 2016-02-24 | $4.76M 10-K · filed 2014-03-03 | |
| 2013-09-30 | $415.00K 10-K · filed 2015-02-27 | $1.74M derived: sum of 2 quarters · filed 2015-02-27 | $3.06M 10-Q · filed 2014-11-04 | -$121.29M derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-06-30 | $1.32M 10-K · filed 2015-02-27 | $2.64M 10-Q · filed 2014-08-07 | -$121.70M derived: sum of 3 quarters · filed 2015-02-27 | -$120.27M derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-03-31 | $1.32M 10-K · filed 2015-02-27 | $1.34M 10-Q · filed 2014-05-07 | -$123.03M derived: sum of 2 quarters · filed 2015-02-27 | -$121.59M derived: sum of 3 quarters · filed 2015-02-27 | -$120.17M derived: sum of 4 quarters · filed 2015-02-27 | |
| 2012-12-31 | -$124.35M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | -$122.92M derived: sum of 2 quarters · filed 2015-02-27 | -$121.49M derived: sum of 3 quarters · filed 2015-02-27 | $5.61M 10-K · filed 2015-02-27 | $135.76M 10-K · filed 2013-02-26 | |
| 2012-09-30 | $1.43M 10-Q · filed 2012-10-31 | $2.86M derived: sum of 2 quarters · filed 2012-10-31 | $129.96M 10-Q · filed 2012-10-31 | $135.32M derived: sum of 4 quarters · filed 2014-03-03 | ||
| 2012-06-30 | $1.43M 10-Q · filed 2012-08-01 | $128.53M 10-Q · filed 2012-08-01 | $133.89M derived: sum of 3 quarters · filed 2014-03-03 | $140.32M derived: sum of 4 quarters · filed 2014-03-03 | ||
| 2012-03-31 | $127.10M 10-Q · filed 2012-05-02 | $132.46M derived: sum of 2 quarters · filed 2014-03-03 | $138.89M derived: sum of 3 quarters · filed 2014-03-03 | $145.28M derived: sum of 4 quarters · filed 2014-03-03 | ||
| 2011-12-31 | $5.36M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $11.79M derived: sum of 2 quarters · filed 2014-03-03 | $18.18M derived: sum of 3 quarters · filed 2014-03-03 | $24.51M 10-K · filed 2014-03-03 | ||
| 2011-09-30 | $6.43M 10-Q · filed 2012-10-31 | $12.82M derived: sum of 2 quarters · filed 2012-10-31 | $19.15M 10-Q · filed 2012-10-31 | |||
| 2011-06-30 | $6.39M 10-Q · filed 2012-08-01 | $12.72M 10-Q · filed 2012-08-01 | ||||
| 2011-03-31 | $6.33M 10-Q · filed 2012-05-02 | |||||
| 2010-12-31 | $24.22M 10-K · filed 2013-02-26 | |||||
| 2009-12-31 | $24.37M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |